Michael Gnant
Impact in
- Cancer Research top 0.02%
- Breast Cancer Treatment Studies
- Oncology top 0.05%
- HER2/EGFR in Cancer Research
- Bone health and treatments
Papers in
- Oncology 261
- Cancer Treatment and Pharmacology 71
- HER2/EGFR in Cancer Research 56
- Bone health and treatments 51
- Cancer Research 189
- Breast Cancer Treatment Studies 161
- Co-authors
- Nadia Harbeck (16 shared papers)R. Jakesz (175 shared papers)Donna Wright (1 shared paper)C A Cull (1 shared paper)Honora H. McElroy (1 shared paper)E M Kohner (1 shared paper)R R Holman (1 shared paper)David R. Hadden (1 shared paper)
- Journals
- Journal of Clinical Oncology (89 papers)Cancer Research (37 papers)Annals of Oncology (28 papers)Breast Care (25 papers)European Journal of Cancer (21 papers)
- Partner nations
- AustriaUnited StatesGermany
In The Last Decade
Michael Gnant
534 papers receiving 38.0k citations
Michael Gnant's Hit Papers
Peers
Comparison fields: 5 of 180
- Cancer Research 8.4k
- Oncology 10.3k
- Endocrinology, Diabetes and Metabolism 5.7k
- Surgery 6.8k
- Pulmonary and Respiratory Medicine 4.3k
Countries citing papers authored by Michael Gnant
This map shows the geographic impact of Michael Gnant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Gnant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Gnant more than expected).
Fields of papers citing papers by Michael Gnant
This network shows the impact of papers produced by Michael Gnant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Gnant. The network helps show where Michael Gnant may publish in the future.
Co-authors
The 25 scholars most cited alongside Michael Gnant, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 562 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Hit paper breakdown → | 1998 | 7367 |
| 2 | Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Hit paper breakdown → | 1994 | 7099 |
| 3 | Breast cancer Hit paper breakdown → | 2019 | 2112 |
| 4 | Breast cancer Hit paper breakdown → | 2016 | 1818 |
| 5 | Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. MRC Vitamin Study Research Group. Hit paper breakdown → | 1991 | 1602 |
| 6 | Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial Hit paper breakdown → | 2005 | 680 |
| 7 | Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen Hit paper breakdown → | 2009 | 609 |
| 8 | Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019 Hit paper breakdown → | 2019 | 449 |
| 9 | Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2 Hit paper breakdown → | 2014 | 432 |
| 10 | 2007 | 426 | |
| 11 | Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis Hit paper breakdown → | 2013 | 399 |
| 12 | 2011 | 368 | |
| 13 | Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer Hit paper breakdown → | 2016 | 364 |
| 14 | 2015 | 361 | |
| 15 | 2007 | 358 | |
| 16 | 2011 | 355 | |
| 17 | Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. | 2002 | 344 |
| 18 | 2008 | 294 | |
| 19 | 2006 | 264 | |
| 20 | 2013 | 245 |
About Michael Gnant
Michael Gnant is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Genetics and Molecular Biology, having authored 562 papers that have together received 39.5k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (161 papers), Advanced Breast Cancer Therapies (115 papers), Estrogen and related hormone effects (73 papers), Cancer Treatment and Pharmacology (71 papers), HER2/EGFR in Cancer Research (56 papers), Bone health and treatments (51 papers), Radiopharmaceutical Chemistry and Applications (36 papers) and Breast Lesions and Carcinomas (26 papers). The work is most often cited by research in Cancer Research (8.4k citations), Oncology (10.3k citations), Endocrinology, Diabetes and Metabolism (5.7k citations), Surgery (6.8k citations) and Pulmonary and Respiratory Medicine (4.3k citations). Michael Gnant has collaborated with scholars based in Austria, United States and Germany. Frequent co-authors include Nadia Harbeck, R. Jakesz, Donna Wright, C A Cull, Honora H. McElroy, E M Kohner, R R Holman, David R. Hadden, Matthews and R. C. Turner. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Annals of Oncology, Breast Care and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.